Eli Lilly

“Eli Lilly has announced that it plans to submit Orforglipron to the FDA for regulatory review this year (2025) for weight loss, and in 2026 for type 2 diabetes.”

2025 2026

Read on citations.press →Source ↗

health · Medical News Today

The Zepbound Savings Card can reduce out‑of‑pocket cost to as low as $25 for a 3‑month prescription for those with commercial insurance coverage.

“as low as $25 for a 3-month prescription.”

25 $

Read on citations.press →Source ↗

health · Medical News Today

An authorized generic version of Zepbound will not be available until at least the 2030s due to active patents held by the manufacturer.

“until at least the 2030s.”

at least 2030 year

Read on citations.press →Source ↗

Eli Lilly has overtaken Novo Nordisk in U.S. market share—60.9% to 38.8% as of August—according to market data.

Eli Lilly disclosed 11 biotech acquisitions in the first half of 2026.

Eli Lilly invested $40 million in Absci to support the development of the injectable antibody ABS‑201.

Eli Lilly announced the results of a late-stage Phase 3 trial for Orforglipron in August 2025.

Eli Lilly plans to submit Orforglipron to the FDA for regulatory review in 2025 for weight loss and in 2026 for type 2 diabetes.

The Zepbound Savings Card can reduce out‑of‑pocket cost to as low as $25 for a 3‑month prescription for those with commercial insurance coverage.

An authorized generic version of Zepbound will not be available until at least the 2030s due to active patents held by the manufacturer.

Eli Lilly invested $40 million in Absci to support the development of the injectable antibody ABS‑201.